A milestone, which allowed for better differentiation between benign lesions and ovarian cancer, was the introduction of the Risk of Ovarian Malignancy Algorithm (ROMA), which combines the determination of HE4 and CA125 in one test, accounting for a patient’s menopausal status. This evidence concerns the gene WFDC2 and ovarian carcinoma.